BVS
ANALYST COVERAGE6 analysts
BUY
+22.3%upside to target
Buy
467%
Hold
233%
4 Buy (67%)2 Hold (33%)0 Sell (0%)
Full report →
PRICE
Prev Close
10.58
Open
10.58
Day Range10.43 – 10.87
10.43
10.87
52W Range5.81 – 11.25
5.81
11.25
89% of range
VOLUME & SIZE
Avg Volume
457.5K
FUNDAMENTALS
P/E Ratio
25.9x
EPS (TTM)
Div Yield
No dividend
Beta
1.04
Market-like
TECHNICAL
RSI (14)
73
Overbought
Upcoming Events
EEarnings Report
Tomorrow
May 20
DEx-Dividend
In 90 days
Aug 17
PDividend Pay
In 104 days
Aug 31
Key MetricsTTM
Market Cap$720.16M
Revenue TTM$576.30M
Net Income TTM$28.48M
Free Cash Flow$100.63M
Gross Margin67.8%
Operating Margin10.6%
Net Margin4.9%
Return on Equity16.3%
Return on Assets4.4%
Debt / Equity0.10
Current Ratio1.69
EPS TTM$0.42

BVS News

About

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.

Industry
Surgical and Medical Instrument Manufacturing
Anthony D'AdamioSenior Vice President, General Counsel & Corporate Secretary
Dave VennerSenior Vice President & GM of Surgical
Mark SingletonSenior Vice President & Chief Financial Officer
Helen LeupoldSenior Vice President & Chief Human Resources Officer
Katrina J. ChurchSenior Vice President & Chief Compliance Officer
David CrawfordVice President of Investor Relations & Treasurer
Mike CroweSenior Vice President of Operations
Robert ClaypoolePresident, Chief Executive Officer & Director